65,437 trials
Recurrent Fallopian Tube Carcinoma · Recurrent Ovarian Carcinoma · Recurrent Primary Peritoneal Carcinoma
Primary: Response Rate (RR) Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 — 3; 15; 5 Participants
Lateral Canthal Lines · Crow's Feet
Primary: Number of Participants With a Response Defined as Change in IGA-C (Investigators Global Assessment) Score by at Least 2 Ordinals From Baseline to Week 4 — 2; 0; 1…
Cystic Fibrosis
Primary: Absolute Change in Lung Clearance Index 2.5 (LCI2.5) — -0.02; -2.29 index — p=<0.0001
Cardiac Disease
Primary: Number of Participants With Adjudicated Bleeding Events Within the Main Treatment Period — 1; 1; 0; 0 Participants
Acne Vulgaris
Primary: Change From Baseline in Inflammatory Lesion Counts at Week 12 — 22.3; 19.0 inflammatory lesions
Mantle Cell Lymphoma
Primary: Progression-free Survival (PFS) — 52.9; 80.6 months — p=0.011
Type 2 Diabetes
Primary: Change in Hemoglobin A1c (HbA1c) — -0.33; -0.70 mmol/mol
Multiple Myeloma
Primary: Number of Participants With VGPR or Better Response to Induction — 6 Participants — p=0.597
Bulimia Nervosa
Primary: Change in Binge Eating Sum Score — -0.60; 0.89 score on a scale
Bone Fracture
Primary: Primary Outcome: Number of Participants With Minor Side Effects and Significant Adverse Events — 0; 0; 41; 25 Participants
Cannabis Use
Primary: Cannabis Self-administration — 5.75; 9.2; 5.75; 7.5 puffs of cannabis chosen
Carcinoma, Basal Cell
Primary: Objective Response Rate (ORR) as Assessed by Independent Central Review (ICR) — 22.2; 32.1 Percentage of Participants
Uncontrolled Gout · Kidney Transplant
Primary: Percentage of Serum Uric Acid (sUA) < 6 mg/dL Responders During Month 6 — 88.9 percentage of participants
Post-bariatric Hypoglycemia
Primary: Number of Participants With Meal-provoked Hypoglycemia, Defined as Sensor Glucose <65 mg/dL — 1; 5 participants — p=0.103
COVID-19
Primary: Pooled Analysis (Phase 3 [Cohort 1] and Phase 2 [Cohort 1A]): Time-weighted Average (TWA) Change in Viral Load in Nasopharyngeal (NP) Samples Based on Seronegative mFAS…